Mon 03/04/2024 07:00 AM
French pharmaceutical solution and specialty chemicals producer Seqens expects full-year 2024 adjusted EBITDA to fall another 11% from its full-year 2023 results, which missed budget following a third-quarter earnings
collapse and subsequent weak fourth-quarter numbers. However, even that looks potentially over optimistic given that the 2024 budget assumes a recovery in active ingredient para-aminophenol, or PAP, earnings that is still far from certain, sources...
This article is an example of the content you may receive if you subscribe to a product of Reorg Research, Inc. or one of its affiliates (collectively, “Reorg”). The information contained herein should not be construed as legal, investment, accounting or other professional services advice on any subject. Reorg, its affiliates, officers, directors, partners and employees expressly disclaim all liability in respect to actions taken or not taken based on any or all the contents of this publication. Copyright © 2024 Reorg Research, Inc. All rights reserved.